title: Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis.
abstract: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently complicated by transfusion dependent anemia. Both anemia and transfusion-dependence are associated with a poor outcome, at least in part because of toxic effects of iron overload (IOL). Iron-chelating therapy (ICT) is increasingly used in order to prevent IOL in this setting. Here, we describe the case of a 73-year-old man affected by PMF and severe transfusion-dependent anemia who experienced a dramatic erythroid response after being treated with deferasirox to prevent IOL.
authors.affiliation: Department of Hematology and Oncology, IRCCS AOU San Martino-IST, Largo Rosanna Benzi 10, 16132 Genoa, Italy.
authors.forename: Del Corso
authors.initials: del C
authors.lastname: Lisette
authors.forename: Balleari
authors.initials: B
authors.lastname: Enrico
authors.forename: Arboscello
authors.initials: A
authors.lastname: Eleonora
authors.forename: Ghio
authors.initials: G
authors.lastname: Riccardo
authors.forename: Mencoboni
authors.initials: M
authors.lastname: Manlio
authors.forename: Racchi
authors.initials: R
authors.lastname: Omar